rhIL-15
Trials 9 · a red edge is where a trial was stopped
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIL-15 | “The first-in-human clinical trial with human bolus intravenous infusion IL15 (rhIL15) was limited by treatment-associated toxicity.” PMID 31142503 ↗ May 201910“Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021 “Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body” NCT01021059 ↗ “Recombinant human interleukin-15 (rhIL-15)” NCT01875601 ↗ |
| Known as | IL-15 | “Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2...” NCT03905135 ↗4“Recombinant human Interleukin-15 (rhIL-15) is a stimulatory cytokine that promotes the differentiation and activation of NK cells, monocytes, and long-term cluster of...” NCT03759184 ↗ “The first-in-human clinical trial with human bolus intravenous infusion IL15 (rhIL15) was limited by treatment-associated toxicity.” PMID 31142503 ↗ May 2019 “Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body” NCT01021059 ↗ “recombinant human interleukin (IL)-15 (rhIL-15)” NCT06995872 ↗ |
| Known as | Interleukin-15 | “Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2...” NCT03905135 ↗2“Recombinant human Interleukin-15 (rhIL-15) is a stimulatory cytokine that promotes the differentiation and activation of NK cells, monocytes, and long-term cluster of...” NCT03759184 ↗ “Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions.” PMID 33883258 ↗ Apr 2021 |
| Known as | Recombinant human Interleukin-15 | “Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body” NCT01021059 ↗ |
| Action | Activate | “IL-15 has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells.” PMID 25403209 ↗ Nov 2014 |
| Modality | Protein / enzyme biologic | “Escherichia coli-produced rhIL-15.” PMID 25403209 ↗ Nov 2014 |
| Route | Intravenous | “rhIL-15 will be given intravenously once a day for 12 consecutive days” NCT01021059 ↗ |